- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT01107834
Heart Function in HIV-Negative Children Exposed to HIV and HAART
Left Ventricular Function in HIV-Negative Children Exposed to HIV and HAART In Utero
Обзор исследования
Статус
Условия
Подробное описание
Significance:
Approximately 700,000 children annually are born to HIV-infected mothers throughout the world, but with the advent of perinatal highly active antiretroviral therapy (HAART), the majority of children are born uninfected in Westernized nations and those uninfected are increasing in developing nations. Uninfected children exposed to HIV and HAART in utero, have subclinical left ventricular dysfunction (LVD) at birth which may predispose them to heart failure, conduction abnormalities and myocardial infarction later in life. The impact of this LVD on future cardiac risk is unclear as it is unknown if LVD in these children persist, worsen or resolve in pre-pubescence.
Study objectives:
The objective of this study is to characterize left ventricular function in HIV-negative pre-pubertal children born to HIV+ women and exposed to HIV and HAART in utero and compare them to age and gender matched healthy children born to HIV-negative women. Through this objective we will determine if LVD in HIV-negative children born to HIV+ women and exposed to HAART in utero persists, worsens, or resolves during pre-pubescence. If LVD persists or worsens in pre-pubescence, these data will lead to future studies examining mechanisms of and treatments for LVD in these children and will significantly impact the clinical monitoring and care of these children. If LVD resolves during pre-pubescence, then these data will provide important information that clinical cardiac monitoring may not be critical in this population.
Methods:
We plan to examine left ventricular function in 30 HIV-negative children born to HIV+ women and exposed to HAART in utero and compare them to 30 healthy age and gender matched children born to HIV-negative women. Left ventricular function will be examined by 2-D, Doppler and Tissue Doppler imaging echocardiography using a General Electric Vivid 7® ultrasound machine. Left ventricular measures will include left ventricular structure and dimensions, systolic and diastolic flow rates, wall velocities during systole and diastole and systolic and diastolic strain and strain rates (sensitive measures of myocardial contractility). Echocardiographic measures will take place in the Cardiovascular Imaging Laboratory (CVIL) at Washington University School of Medicine by a certified cardiac ultrasonographer and data will be processed, analyzed and interpreted by the ultrasonographer, a consulting cardiologist and the principal investigator.
Outcomes:
Primary outcomes will include measures of left ventricular function: left ventricular mass, left ventricular end diastolic dimension, fractional shortening, systolic and diastolic wall velocities (tissue Doppler imaging) and systolic and diastolic strain and strain rates (2-D speckle tracking methodology).
Тип исследования
Регистрация (Действительный)
Контакты и местонахождение
Места учебы
-
-
Missouri
-
St. Louis, Missouri, Соединенные Штаты, 63110
- Washington University School of Medicine
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Описание
Inclusion Criteria:
- Age 5-12 years
- Tanner stage I-III
- Born to HIV+ mother
- No HIV infection
- Had taken standard of care prophylactic HAART at birth-1 month of age
- Child currently not taking medications or have medical diagnosis that would affect left ventricular function
- Mother was taking HAART during pregnancy (standard of care)
- Mother was not using illegal drugs during pregnancy
- No intrauterine growth restriction diagnosis during pregnancy
- During pregnancy, mother will not have a diagnosis of type 2 diabetes or gestational diabetes.
Exclusion Criteria:
- Age 5-12 years
- Tanner stage I-III
- Born to HIV-negative mother
- Mother was not a frequent exerciser during pregnancy (>2x/week)
- Mother will not have gestational diabetes or a diagnosis of type 2 diabetes during pregnancy of the child being studied
- Child currently not taking medications or have medical diagnosis that would affect left ventricular function
Учебный план
Как устроено исследование?
Детали дизайна
Когорты и вмешательства
Группа / когорта |
|---|
|
Healthy Control
HIV-negative children born to healthy, HIV-negative women
|
|
Exposed to HIV/HAART
HIV-negative children exposed to HIV and HAART in utero
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Left Ventricular Mass Index
Временное ограничение: Baseline
|
left ventricular mass index measured by 2D echocardiography
|
Baseline
|
|
Fractional Shortening
Временное ограничение: Baseline
|
Fractional shortening measured by M-mode cardiography
|
Baseline
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Global Strain Rate
Временное ограничение: Baseline
|
Myocardial deformation (a measure of heart contractility) measured by speckel tracking echocardiography
|
Baseline
|
|
Systolic Myocardial Velocity During Systole (S')
Временное ограничение: Baseline
|
Systolic myocardial velocity during systole measured by tissue Doppler echocardiography
|
Baseline
|
|
Early to Late Diastolic Filling Ratio
Временное ограничение: Baseline
|
Early to late diastolic filling ratio measured by tissue Doppler echocardiography
|
Baseline
|
|
Myocardial Wall Velocity During Early Diastole
Временное ограничение: Baseline
|
Myocardial wall velocity during early diastolemeasured by tissue Doppler imaging
|
Baseline
|
Соавторы и исследователи
Соавторы
Следователи
- Главный следователь: William T Cade, PhD, Washington University School of Medicine
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Оценивать)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- РНК-вирусные инфекции
- Вирусные заболевания
- Инфекции
- Инфекции, передающиеся через кровь
- Передающиеся заболевания
- Заболевания, передающиеся половым путем, вирусные
- Заболевания, передающиеся половым путем
- Лентивирусные инфекции
- Ретровирусные инфекции
- Синдромы иммунологического дефицита
- Заболевания иммунной системы
- ВИЧ-инфекции
Другие идентификационные номера исследования
- 10-0121
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .